GlaxoSmithKline’s product to help protect against cervical cancer, called Cervarix, shows that it works against five common cervical cancer-causing viruses. There are two common types of cervical cancer, and three less common types.

Cervarix offered “11 to 16 percent extra protection against cervical cancer over and above the protection afforded by efficacy against the two most common types alone.” Research indicates that this is the first time protection has been shown against “pre-cancerous lesions not containing the two most common virus types.”
This is good news for cervical cancer research. Cervarix is approved in 90 countries, but has …read more